Zanolimumab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by The chemistds (talk | contribs) at 21:03, 16 October 2011 (No ChemSpider ID for this record). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Zanolimumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetCD4
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
UNII
KEGG
Chemical and physical data
Molar mass147 kDa
  (verify)

Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, melanoma [2], cutaneous and peripheral T-cell lymphoma.[3][4]

References

  1. ^ Genmab initiates Phase II Study with HuMax-CD4
  2. ^ http://www.tenxbiopharma.com/development.shtml
  3. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
  4. ^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Zanolimumab&oldid=455905695"